Somatic Variant: BRAF

Targeted agents, such as vemurafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.

Citations:

• Wagle, Nikhil, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer discovery 4.1 (2014): 61-68.